Nov 5, 4:07 PM ET
Solventum reported third-quarter 2026 net sales of $1.9 billion, a 7.0 percent decrease on a reported basis due to prior-quarter advance orders placed ahead of ERP cutovers. Despite the sales decline and a GAAP net loss of $12 million, the company raised its full-year adjusted diluted EPS guidance to a range of $7.20 to $7.30 and expects organic sales growth toward the high end of its +2.5% to +3.0% range.
- Q3 2026 net sales were $1.9 billion, reflecting a 7.0% reported decrease and a 2.8% organic decrease.
- GAAP diluted earnings per share was $(0.07), while adjusted diluted earnings per share was $1.45.
- Full-year adjusted EPS guidance was raised to $7.20 to $7.30 from the prior range of $7.10 to $7.20.
Read the filing on SEC.gov ↗
Aug 5, 4:17 PM ET
Solventum reported second-quarter 2026 net sales of $2.2 billion, up 2.2% reported and 9.5% organic, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $2.55. The company raised its full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow, and announced its intent to separate the Health Information Systems segment. GAAP results were weaker in some areas, including a GAAP operating margin of 8.2% versus 9.9% a year earlier.
- Q2 net sales of $2.2 billion, up 2.2% reported and 9.5% organic; GAAP diluted EPS $0.53 vs. $0.51 a year earlier
- Adjusted diluted EPS of $2.55 vs. $1.69 in Q2 2025, a 50.9% increase
- 2026 adjusted EPS guidance raised to $7.10 to $7.20, from the upper end of the prior $6.40 to $6.60 range
- Intent to separate Health Information Systems segment; six-month net income was $105 million, down 53.7%
Read the filing on SEC.gov ↗
Jul 20, 4:15 PM ET
Solventum appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026, replacing Mary Wilcox, who is retiring. He will also serve as principal accounting officer for SEC reporting and report to CFO Wayde McMillan. The filing describes the change as a planned succession in a key finance role, with no financial results disclosed.
- Neil Zieselman, age 50, previously served as Senior Vice President, Corporate Finance and Controller at Surgery Partners, Inc. since May 2022
- Compensation includes a 50% target annual bonus, a $500,000 long-term incentive target award and a $130,000 cash sign-on bonus
- Initial grant of $600,000 in restricted stock units vests in three equal installments over three years
- Board appointed him on July 16, 2026, in connection with Mary Wilcox's previously announced retirement
Read the filing on SEC.gov ↗
May 27, 4:23 PM ET
Solventum's Talent Committee approved a new Executive Severance Plan on May 21, 2026, effective June 1, 2026, replacing the prior plan from April 1, 2024. The filing says the new plan changes severance terms for executives, including a lump-sum COBRA payment for the CEO and direct reports, and provides for forfeiture of certain post-effective date equity awards.
- Plan adopted May 21, 2026 by the Talent Committee of the Board, effective June 1, 2026, replacing the Prior Plan effective April 1, 2024
- CEO direct reports generally receive 12 months of base salary plus prorated incentive pay; executives eligible for 18 months keep that amount for two years
- CEO and direct reports receive a lump-sum payment equal to COBRA premiums for the severance period
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
